Home › Funds › General Catalyst Group Management, LLC › AVBP

General Catalyst Group Management, LLC position in AVBP

ARRIVENT BIOPHARMA INC COM · Health Care

General Catalyst Group Management, LLC reported holding 1,494,786 shares of AVBP (ARRIVENT BIOPHARMA INC COM) in its Q2 2026 13F filing — a position valued at US$51.9M, representing 27.55% of its reported portfolio and ranking #1 among its reported holdings. General Catalyst Group Management, LLC has disclosed AVBP holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)1.49M sh
Reported value held$51.93M
Portfolio Weight27.55%
First reportedQ1 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How General Catalyst Group Management, LLC's AVBP position evolved

General Catalyst Group Management, LLC first disclosed a stake in AVBP in Q1 2024 at 1,494,786 shares (US$26.7M). The position peaked in Q2 2026 at 1,494,786 shares, worth US$51.9M. Across 10 filings, General Catalyst Group Management, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,494,786 shares valued at US$51.9M.

Quarter by quarter

QuarterSharesValueChange
Q1 2024 1.49M $26.70M New
Q2 2024 1.49M $27.73M Hold
Q3 2024 1.49M $35.13M Hold
Q4 2024 1.49M $39.82M Hold
Q1 2025 1.49M $27.64M Hold
Q2 2025 1.49M $32.54M Hold
Q3 2025 1.49M $27.58M Hold
Q4 2025 1.49M $30.08M Hold
Q1 2026 1.49M $34.48M Hold
Q2 2026 1.49M $51.93M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AVBP and 13F data

AVBP (ARRIVENT BIOPHARMA INC COM) is a Health Care company. 60 other funds we track also report a position in AVBP — the largest reported positions include MONTANOVA CAPITAL, LLC (US$156.9M), INFINITUM ASSET MANAGEMENT, LLC (US$154.2M), Hillhouse Capital (HHLR Advisors) (US$136.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AVBP

All AVBP fund holders →

FAQ

How long has General Catalyst Group Management, LLC held AVBP?

General Catalyst Group Management, LLC has disclosed AVBP holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is General Catalyst Group Management, LLC's current position in AVBP?

As of Q2 2026, General Catalyst Group Management, LLC holds 1.49M shares of AVBP (ARRIVENT BIOPHARMA INC COM), valued at $51.93M, representing 27.55% of its reported portfolio and ranking #1.

Has General Catalyst Group Management, LLC been buying or selling AVBP?

In the latest 13F filing (Q2 2026), General Catalyst Group Management, LLC held unchanged its position in AVBP. The position peaked in Q2 2026 at 1.49M shares.

Which other funds hold AVBP?

Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), among 60 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.